By : Business Editor
Jordan Daily - Gulf Pharmaceutical Industries (Julphar) reported higher revenue and a sharp rise in annual profit for the year ended Dec. 31, 2025, driven by operational improvements and strategic execution.
Revenue increased 8.4% year-on-year to AED 1.08 billion ($293 million) from continuing operations, with constant-currency growth at 9.0%, Julphar said in a statement seen by Jordan Daily.
Net profit rose to AED 173.3 million from AED 44.9 million a year earlier, supported by a one-off capital gain of AED 111.2 million. Net operating profit from continuing operations reached AED 43.9 million, indicating improved underlying performance.
EBITDA from continuing operations climbed 22.2% to AED 109.4 million.
Total assets stood at AED 1.78 billion, while shareholders’ equity reached AED 959.8 million.
“The company’s performance reflects a clear strategic direction and a commitment to building lasting value beyond short-term results,” Chairman Sheikh Saqer Bin Humaid Al Qasimi said. “Continued focus on resilience, responsible growth, and long-term sustainability remains central to strengthening the company’s position and supporting its future ambitions across evolving markets.”
Chief Executive Basel Ziyadeh said: “These results highlight our continued progress in maintaining a strong balance between investments, a solid capital structure, and sustainable long-term shareholder value creation.”
